This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock CPSR vs. GMTX, MOR, ZYME, CALT, ETHZ, SBTX, AVTE, NLTX, BIOA, and VIRIShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include Gemini Therapeutics (GMTX), MorphoSys (MOR), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), and Virios Therapeutics (VIRI). Capstar Special Purpose Acquisition vs. Its Competitors Gemini Therapeutics MorphoSys Zymeworks Calliditas Therapeutics AB (publ) Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Virios Therapeutics Capstar Special Purpose Acquisition (NYSE:CPSR) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends. Which has higher valuation & earnings, CPSR or GMTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/AGemini TherapeuticsN/AN/A-$71.87M-$1.00-73.00 Does the media favor CPSR or GMTX? In the previous week, Gemini Therapeutics had 1 more articles in the media than Capstar Special Purpose Acquisition. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Capstar Special Purpose Acquisition. Gemini Therapeutics' average media sentiment score of 0.67 beat Capstar Special Purpose Acquisition's score of 0.00 indicating that Gemini Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Capstar Special Purpose Acquisition Neutral Gemini Therapeutics Positive Which has more volatility & risk, CPSR or GMTX? Capstar Special Purpose Acquisition has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Is CPSR or GMTX more profitable? Capstar Special Purpose Acquisition's return on equity of 0.00% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Capstar Special Purpose AcquisitionN/A N/A N/A Gemini Therapeutics N/A -38.78%-35.88% Do institutionals & insiders have more ownership in CPSR or GMTX? 64.9% of Capstar Special Purpose Acquisition shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCapstar Special Purpose Acquisition and Gemini Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$855.95M$1.06B$6.11B$21.91BDividend YieldN/A4.84%5.73%3.62%P/E RatioN/A1.2585.3630.12Price / SalesN/A30.67607.4466.99Price / CashN/A17.6437.4624.26Price / Book-21.037.6612.424.70Net Income-$15.30M-$7.71M$3.32B$1.01B Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$24.81-0.1%N/A+280.2%$855.95MN/A0.002GMTXGemini TherapeuticsN/A$67.89-2.0%N/A+50.7%$2.94BN/A-67.8930MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ZYMEZymeworks0.066 of 5 stars$16.68+1.1%N/AN/A$1.25B$76.30M-17.20460News CoverageAnalyst UpgradeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ETHZFlag Ship AcquisitionN/A$2.32-0.4%N/AN/A$381.48MN/A-0.157Stock SplitGap DownSBTXSilverback TherapeuticsN/A$10.33+0.6%N/A-24.7%$372.48MN/A-4.2783High Trading VolumeAVTEAerovate TherapeuticsN/A$9.04-1.1%N/A-87.9%$262.02MN/A-3.0220News CoverageHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$23.47+1.6%N/A-36.0%$220.57MN/A-7.5590High Trading VolumeBIOABioAge Labs0.1874 of 5 stars$5.67+1.3%N/AN/A$203.27MN/A0.00N/AVIRIVirios TherapeuticsN/A$6.76+1.0%$5.00-26.0%+50.0%$130.18MN/A-25.045News Coverage Related Companies and Tools Related Companies Gemini Therapeutics Competitors MorphoSys Competitors Zymeworks Competitors Calliditas Therapeutics AB (publ) Competitors Flag Ship Acquisition Competitors Silverback Therapeutics Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors BioAge Labs Competitors Virios Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
